Los Angeles, February 24, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce completion of its Seed Preferred 3 Stock financing. Trethera raised an aggregate of $3.2 million from its existing investors, which funds will be […]
Los Angeles, January 7, 2021— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515, Trethera’s first-in-class drug for the treatment of acute disseminated encephalomyelitis (ADEM). […]
Los Angeles, December 8, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, is pleased to announce that distinguished researcher Michael Shepard, PhD has joined Trethera’s Scientific Advisory Board. Dr. Shepard is a recipient of numerous biotechnology patents and scientific awards […]
Los Angeles, November 2, 2020— Trethera Corporation (“Trethera”), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer and autoimmune diseases is pleased to announce that it has filed a provisional patent application with the US Patent & Trademark Office for the company’s first-in-class drug TRE-515. If granted, […]